CN114040776A - Tlr激动剂与抗ox40抗体或其抗原结合片段联合在制备治疗肿瘤的药物中的用途 - Google Patents

Tlr激动剂与抗ox40抗体或其抗原结合片段联合在制备治疗肿瘤的药物中的用途 Download PDF

Info

Publication number
CN114040776A
CN114040776A CN202080045367.9A CN202080045367A CN114040776A CN 114040776 A CN114040776 A CN 114040776A CN 202080045367 A CN202080045367 A CN 202080045367A CN 114040776 A CN114040776 A CN 114040776A
Authority
CN
China
Prior art keywords
seq
carcinoma
antibody
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080045367.9A
Other languages
English (en)
Inventor
蒋家骅
廖成
张连山
孙飘扬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN114040776A publication Critical patent/CN114040776A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

本发明公开了TLR激动剂与抗OX40抗体或其抗原结合片段联合在制备治疗肿瘤的药物中的用途。具体而言，TLR激动剂为式(I)所示化合物或其可药用盐。

Description

PCT国内申请，说明书已公开。

Claims (16)

  1. PCT国内申请，权利要求书已公开。
CN202080045367.9A 2019-06-28 2020-06-28 Tlr激动剂与抗ox40抗体或其抗原结合片段联合在制备治疗肿瘤的药物中的用途 Pending CN114040776A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910571681X 2019-06-28
CN201910571681 2019-06-28
PCT/CN2020/098409 WO2020259667A1 (zh) 2019-06-28 2020-06-28 Tlr激动剂与抗ox40抗体或其抗原结合片段联合在制备治疗肿瘤的药物中的用途

Publications (1)

Publication Number Publication Date
CN114040776A true CN114040776A (zh) 2022-02-11

Family

ID=74060753

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080045367.9A Pending CN114040776A (zh) 2019-06-28 2020-06-28 Tlr激动剂与抗ox40抗体或其抗原结合片段联合在制备治疗肿瘤的药物中的用途

Country Status (3)

Country Link
CN (1) CN114040776A (zh)
TW (1) TW202114688A (zh)
WO (1) WO2020259667A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112957475B (zh) * 2021-02-04 2022-07-22 李文峰 一种预防和或治疗肿瘤的组合物及应用
CN116059377A (zh) * 2021-07-19 2023-05-05 百奥泰生物制药股份有限公司 抗ox40抗体在联合用药中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017084494A1 (zh) * 2015-11-19 2017-05-26 江苏恒瑞医药股份有限公司 苯并呋喃类衍生物、其制备方法及其在医药上的应用
CN108136011A (zh) * 2015-08-03 2018-06-08 星座制药公司 Ezh2抑制剂和调节性t细胞功能的调制

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009065618A2 (de) * 2007-11-22 2009-05-28 Biontex Laboratories Gmbh Verbesserung von transfektionsergebnissen nicht-viraler genliefersysteme durch beeinflussung des angeborenen immunsystems
GB201116092D0 (en) * 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
SG11201607969XA (en) * 2014-03-31 2016-10-28 Genentech Inc Anti-ox40 antibodies and methods of use
CN115109158A (zh) * 2015-05-07 2022-09-27 阿吉纳斯公司 抗ox40抗体及其使用方法
WO2017021912A1 (en) * 2015-08-06 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combined tlrs modulators with anti ox40 antibodies
CA3006963A1 (en) * 2015-12-03 2017-06-08 Ludwig Institute For Cancer Research Ltd. Anti-ox40 antibodies and methods of use thereof
CA3033542A1 (en) * 2016-08-30 2018-03-08 Dana-Farber Cancer Institute, Inc. Compositions and uses of biomaterials and activators of innate immunity
EP3546457B1 (en) * 2016-11-28 2021-07-14 Jiangsu Hengrui Medicine Co., Ltd. Pyrazolo-heteroaryl derivative, preparation method and medical use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108136011A (zh) * 2015-08-03 2018-06-08 星座制药公司 Ezh2抑制剂和调节性t细胞功能的调制
WO2017084494A1 (zh) * 2015-11-19 2017-05-26 江苏恒瑞医药股份有限公司 苯并呋喃类衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
WO2020259667A1 (zh) 2020-12-30
TW202114688A (zh) 2021-04-16

Similar Documents

Publication Publication Date Title
US9951143B2 (en) Antibodies against immunogenic glycopeptides, compositions comprising the same and use thereof
TWI712423B (zh) 抗ｔｒｏｐ２抗體-藥物結合物之製造方法
US20210130442A1 (en) Anti-pseudomonas psl binding molecules and uses thereof
EP3712170A1 (en) Cd96 antibody, antigen-binding fragment and pharmaceutical use thereof
WO2012057288A1 (ja) 新規抗ｄｒ５抗体
US8679497B2 (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof
CN114040776A (zh) Tlr激动剂与抗ox40抗体或其抗原结合片段联合在制备治疗肿瘤的药物中的用途
WO2019076277A1 (zh) 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
BR112021005169A2 (pt) um anticorpo anti-ox40, fragmento de ligação ao antígeno do mesmo e uso farmacêutico
US20140065154A1 (en) Tlr3 binding agents
WO2023066401A1 (zh) 一种特异性结合人ctla4的抗体及包含其的药物和试剂盒
EP3086808B1 (en) Anti adam17 antibody and its use for the treatment of cancer
WO2021249542A1 (en) Antibodies binding tnfr2 and uses thereof
AU2009322587B2 (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof
TW202229355A (zh) 抗ｔｎｆｒ２抗體及其應用
CN112500491A (zh) 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途
WO2023143315A1 (zh) 一种靶向ror1的抗体或其抗原结合片段及其应用
WO2021164692A1 (zh) 一种分离的结合抗原psma的蛋白及其用途
JP7315259B2 (ja) 百日咳毒素結合タンパク質
CN110964107B (zh) Met结合分子、其组合和用途
KR20170076332A (ko) 항 Ang2 항체를 포함하는 면역강화제
WO2020188836A1 (ja) 抗ポドプラニン抗体
CN112007034A (zh) Tlr激动剂与免疫检查点抑制剂、vegfr抑制剂联合在制备治疗肿瘤药物中的用途
KR20160104160A (ko) 클라우딘 3 및 4에 대한 단일클론항체 및 그의 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination